NFA
CMTA

Nationwide Fund Advisors’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Nationwide Fund Advisors’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,300
Closed -$427K – 2831
2017
Q3 		$427K Buy
+25,300
New +$413K ﹤0.01% 2259

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nationwide Fund Advisors's CMTA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q4 2017, closing a stake of 25,300 shares — an estimated $427K sold.

Nationwide Fund Advisors first reported a position in CMTA in Q3 2017 and held it in 1 quarter. The position peaked at $427K in Q3 2017. 37 funds tracked by Wall St. Rank hold CMTA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Clementia Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 25,300 Clementia Pharmaceuticals Inc. shares in Q4 2017, an estimated $427K.
  • Nationwide Fund Advisors first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Clementia Pharmaceuticals Inc. position peaked at $427K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.